Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Analysis

Editor-in-Chief

ISSN (Print): 1573-4129
ISSN (Online): 1875-676X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Quantification and Pharmacokinetics Study of Pedunculoside in Rats by Using UPLC-MS/MS

Author(s): Aiping Yang, Jiajia Dong, Huimin Zhao, Qichun Zhang, Xuyu Zhu, Lina Gao, Ning Ding, Caihong Li, Ren Peng, Tulin Lu, Lihong Hu* and Xiachang Wang*

Volume 17, Issue 6, 2021

Published on: 23 April, 2020

Page: [731 - 737] Pages: 7

DOI: 10.2174/1573412916999200423105153

Price: $65

Abstract

Background: Pedunculoside (PE) is a triterpene saponin from the barks of Ilex rotunda, a Traditional Chinese Medicine called Jiubiying, which is used for the treatment of cold and fever, tonsillitis, sore throat, acute and chronic hepatitis. Previous studies have confirmed that crude extract orally has a significant therapeutic effect on myocardial infarction.

Methods: A simple, sensitive, and specific method by using UPLC-MS/MS to study the pharmacokinetics of PE in rats was developed and validated, with ilexsaponin A as an internal standard. Methanol was used as a protein precipitation reagent for blood sample extraction. A Waters Acquity C18 column (2.1 mm × 50 mm, 1.7 μm) was used for chromatographic separation with a gradient elution of CH3CN: 0.1% formic acid (0.3 mL·min-1). Negative ion electrospray ionization was used for detection in multiple reaction monitoring mode.

Results: PE was linear within the concentration range of 0.14-1118.00 ng/mL. The LLOQ was 0.14 ng/mL for the plasma samples. The intra-day and inter-day precision were ranged from 1.18% to 10.48%, while the accuracy ranged from -1.32% to 1.68%, indicating satisfactory precision and accuracy of the assay. The extraction recoveries for PE and IS were ranged from 81.40% to 86.65%, with no significant variation among the three concentrations, respectively. PE remained stable at room temperature (25°C) for 3 h, in auto-sampler (4°C) for 24 h, after three freeze-thaw cycles, and in long-term storage at ‒20°C for 30 days. The PK results of PE indicated its poor oral bioavailability (3.37%).

Conclusion: Non-compartmental pharmacokinetics parameters indicated that PE was rapidly distributed to the tissues and metabolized. The pharmacokinetic data of this paper highlighted the first-time report of PE oral bioavailability with two different administration manners, which will help to better understand how PE metabolized in rats and exerted its pharmacological effect in vivo.

Keywords: Pedunculoside, triterpene, pharmacokinetics, bioavailability, UPLC-MS/MS, methodology validation.

« Previous Next »
Graphical Abstract

[1]
Owan, T.E.; Hodge, D.O.; Herges, R.M.; Jacobsen, S.J.; Roger, V.L.; Redfield, M.M. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N. Engl. J. Med., 2006, 355(3), 251-259.
[http://dx.doi.org/10.1056/NEJMoa052256] [PMID: 16855265]
[2]
Lam, C.S.P.; Donal, E.; Kraigher-Krainer, E.; Vasan, R.S. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur. J. Heart Fail., 2011, 13(1), 18-28.
[http://dx.doi.org/10.1093/eurjhf/hfq121] [PMID: 20685685]
[3]
Go, A.S.; Mozaffarian, D.; Roger, V.L.; Benjamin, E.J.; Berry, J.D.; Blaha, M.J.; Dai, S.; Ford, E.S.; Fox, C.S.; Franco, S.; Fullerton, H.J.; Gillespie, C.; Hailpern, S.M.; Heit, J.A.; Howard, V.J.; Huffman, M.D.; Judd, S.E.; Kissela, B.M.; Kittner, S.J.; Lackland, D.T.; Lichtman, J.H.; Lisabeth, L.D.; Mackey, R.H.; Magid, D.J.; Marcus, G.M.; Marelli, A.; Matchar, D.B.; McGuire, D.K.; Mohler, E.R., III; Moy, C.S.; Mussolino, M.E.; Neumar, R.W.; Nichol, G.; Pandey, D.K.; Paynter, N.P.; Reeves, M.J.; Sorlie, P.D.; Stein, J.; Towfighi, A.; Turan, T.N.; Virani, S.S.; Wong, N.D.; Woo, D.; Turner, M.B. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation, 2014, 129(3), 399-410.
[http://dx.doi.org/10.1161/01.cir.0000442015.53336.12] [PMID: 24446411]
[4]
Braunwald, E. Heart failure. JACC Heart Fail., 2013, 1(1), 1-20.
[http://dx.doi.org/10.1016/j.jchf.2012.10.002] [PMID: 24621794]
[5]
Ponikowski, P.; Anker, S.D.; AlHabib, K.F.; Cowie, M.R.; Force, T.L.; Hu, S.; Jaarsma, T.; Krum, H.; Rastogi, V.; Rohde, L.E.; Samal, U.C.; Shimokawa, H.; Budi Siswanto, B.; Sliwa, K.; Filippatos, G. Heart failure: preventing disease and death worldwide. ESC Heart Fail., 2014, 1(1), 4-25.
[http://dx.doi.org/10.1002/ehf2.12005] [PMID: 28834669]
[6]
Van Aelst, L.N.L.; Arrigo, M.; Placido, R.; Akiyama, E.; Girerd, N.; Zannad, F.; Manivet, P.; Rossignol, P.; Badoz, M.; Sadoune, M.; Launay, J.M.; Gayat, E.; Lam, C.S.P.; Cohen-Solal, A.; Mebazaa, A.; Seronde, M.F. Acutely decompensated heart failure with preserved and reduced ejection fraction present with comparable haemodynamic congestion. Eur. J. Heart Fail., 2018, 20(4), 738-747.
[http://dx.doi.org/10.1002/ejhf.1050] [PMID: 29251818]
[7]
Kim, E.Y.; Son, Y.J. Association between anemia and cognitive impairment among elderly patients with heart failure. Int. J. Environ. Res. Public Health, 2019, 16(16)e2933
[http://dx.doi.org/10.3390/ijerph16162933] [PMID: 31443272]
[8]
Yancy, C.W.; Jessup, M.; Bozkurt, B.; Butler, J.; Casey, D.E., Jr; Colvin, M.M.; Drazner, M.H.; Filippatos, G.S.; Fonarow, G.C.; Givertz, M.M.; Hollenberg, S.M.; Lindenfeld, J.; Masoudi, F.A.; McBride, P.E.; Peterson, P.N.; Stevenson, L.W.; Westlake, C. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J. Am. Coll. Cardiol., 2017, 70(6), 776-803.
[http://dx.doi.org/10.1016/j.jacc.2017.04.025] [PMID: 28461007]
[9]
Rossignol, P.; Hernandez, A.F.; Solomon, S.D.; Zannad, F. Heart failure drug treatment. Lancet, 2019, 393(10175), 1034-1044.
[http://dx.doi.org/10.1016/S0140-6736(18)31808-7] [PMID: 30860029]
[10]
Chinese Pharmacopoeia Committee. The Chinese Pharmacopoeia, 2015 Part 1; Chemical Industry Publishing House: Beijing, China, 2015.
[11]
Chen, G.; Han, Y.; Feng, Y.; Wang, A.; Li, X.; Deng, S.; Zhang, L.; Xiao, J.; Li, Y.; Li, N. Extract of Ilex rotunda Thunb alleviates experimental colitis-associated cancer via suppressing inflammation-induced miR-31-5p/YAP overexpression. Phytomedicine, 2019.62152941
[http://dx.doi.org/10.1016/j.phymed.2019.152941] [PMID: 31100679]
[12]
Kim, Y.J.; Jung, E.B.; Lee, M.S.; Seo, S.J.; Kim, M.H.; Lee, M.W.; Lee, C.S. Rotundarpene inhibits toll-like receptor 2 activation-induced production of inflammatory mediators in keratinocytes by suppressing the Akt and NF-κB pathways. Int. Immunopharmacol., 2014, 18(2), 325-332.
[http://dx.doi.org/10.1016/j.intimp.2013.12.016] [PMID: 24378401]
[13]
Fan, Z.; Zhou, L.; Xiong, T.; Zhou, J.; Li, Q.; Tan, Q.; Zhao, Z.; Jin, J. Antiplatelet aggregation triterpene saponins from the barks of Ilex rotunda. Fitoterapia, 2015, 101, 19-26.
[http://dx.doi.org/10.1016/j.fitote.2014.11.007] [PMID: 25447155]
[14]
Yang, B.; Zhu, J.P.; Rong, L.; Jin, J.; Cao, D.; Li, H.; Zhou, X.H.; Zhao, Z.X. Triterpenoids with antiplatelet aggregation activity from Ilex rotunda. Phytochemistry, 2018, 145, 179-186.
[http://dx.doi.org/10.1016/j.phytochem.2017.11.005] [PMID: 29169092]
[15]
Wang, C.; Chao, Z.; Sun, W.; Wu, X.; Ito, Y. Enrichment and purification of pedunculoside and syringin from the barks of Ilex rotunda with macroporous resins. J. Liq. Chromatogr. Relat. Technol., 2014, 37(4), 572-587.
[http://dx.doi.org/10.1080/10826076.2012.749499] [PMID: 25104900]
[16]
Liu, C.; Shen, Y.J.; Tu, Q.B.; Zhao, Y.R.; Guo, H.; Wang, J.; Zhang, L.; Shi, H.W.; Sun, Y. Pedunculoside, a novel triterpene saponin extracted from Ilex rotunda, ameliorates high-fat diet induced hyperlipidemia in rats. Biomed. Pharmacother., 2018, 101, 608-616.
[http://dx.doi.org/10.1016/j.biopha.2018.02.131] [PMID: 29518607]
[17]
Wang, W.; Zhao, J.; Li, S.; Lu, Y.; Liu, Y.; Xu, Q.; Li, X.; Khan, I.A.; Yang, S. Five new triterpenoidal saponins from the roots of Ilex cornuta and their protective effects against H2O2-induced cardiomyocytes injury. Fitoterapia, 2014, 99, 40-47.
[http://dx.doi.org/10.1016/j.fitote.2014.08.016] [PMID: 25172104]
[18]
Lin, X.; Peng, P.; Cheng, L.; Chen, S.; Li, K.; Li, Z.Y.; Mo, Y.H.; Zhou, Z.; Li, M. A natural compound induced cardiogenic differentiation of endogenous MSCs for repair of infarcted heart. Differentiation, 2012, 83(1), 1-9.
[http://dx.doi.org/10.1016/j.diff.2011.09.001] [PMID: 22099171]
[19]
Cheng, L.; Gu, X.; Sanderson, J.E.; Wang, X.; Lee, K.; Yao, X.; Liu, H.; Cheung, W.L.; Li, M. A new function of a previously isolated compound that stimulates activation and differentiation of myogenic precursor cells leading to efficient myofiber regeneration and muscle repair. Int. J. Biochem. Cell Biol., 2006, 38(7), 1123-1133.
[http://dx.doi.org/10.1016/j.biocel.2005.12.004] [PMID: 16431151]
[20]
Cheng, L.; Chen, H.; Yao, X.; Qi, G.; Liu, H.; Lee, K.; Lee, K.; Zhang, J.; Chen, S.; Lin, X.; Zhao, W.; Li, J.; Li, M. A plant-derived remedy for repair of infarcted heart. PLoS One, 2009, 4(2)e4461
[http://dx.doi.org/10.1371/journal.pone.0004461] [PMID: 19221596]
[21]
Zhao, W.; Pang, L.; Xu, D.; Zhang, N. LC-MS/MS determination and pharmacokinetic study of pedunculoside in rat plasma after oral administration of pedunculoside and Ilex rotunda extract. Molecules, 2015, 20(5), 9084-9098.
[http://dx.doi.org/10.3390/molecules20059084] [PMID: 25996213]
[22]
Zhao, W.Z.; Ju, W.Z.; Zang, Y.X.; Sun, B.T.; Tan, H.S. Pharmacokinetics of pedunculosid in rat. Chin. J. New Drugs Clin. Rem., 2016, 35(1), 46-49.
[23]
U. S. Food and Drug Administration (FDA), Guidance for industry: bioanalytical method validation. 2013.https://www.fda.gov

Rights & Permissions Print Cite
Article Metrics
29
1
© 2024 Bentham Science Publishers | Privacy Policy